{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T14:42:02Z","timestamp":1793457722729,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"S4","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Summary<\/jats:title>\n          <jats:p>Prostate cancer (PCa) remains a\u00a0leading cause of cancer-related morbidity and mortality in men. Over the past decades, the incidence has risen in all age groups. Prostate-specific membrane antigen (PSMA)-based theranostics, which involve the use of PSMA-targeting radiopharmaceuticals for both diagnostic imaging and therapeutic applications, have become integral in the management of patients with metastatic castration-resistant prostate cancer (mCRPC). The field has witnessed a\u00a0substantial and continuously expanding body of scientific literature, encompassing case reports, original research, systematic reviews and also clinical guidelines. The objective of this joint statement is to enhance awareness of PSMA theranostics and underscore their critical role in contemporary precision oncology. We aim to provide a\u00a0comprehensive yet practical perspective on the current landscape of PSMA-based diagnostic and therapeutic modalities, offering a\u00a0consensus-driven approach to their clinical application.<\/jats:p>","DOI":"10.1007\/s00508-025-02544-4","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T12:02:10Z","timestamp":1749038530000},"page":"157-166","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Use of 177Lu prostate-specific membrane antigen therapy in metastatic castration-resistant prostate cancer"],"prefix":"10.1007","volume":"137","author":[{"given":"Siroos","family":"Mirzaei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Schweighofer-Zwink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidemarie","family":"Ofner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmin","family":"Bektic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harun","family":"Fajkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eisabeth","family":"von Guggenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Ponholzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gero","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Lusuardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gabriel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatjana","family":"Traub-Weidinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Hacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,4]]},"reference":[{"issue":"11","key":"2544_CR1","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1002\/pros.24360","volume":"82","author":"D Withrow","year":"2022","unstructured":"Withrow\u00a0D, Pilleron\u00a0S, Nikita\u00a0N, et\u00a0al. Current and projected number of years of life lost due to prostate cancer: a\u00a0global study. Prostate. 2022;82(11):1088\u201397.","journal-title":"Prostate"},{"issue":"10437","key":"2544_CR2","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","volume":"403","author":"ND James","year":"2024","unstructured":"James\u00a0ND, Tannock\u00a0I, N\u2019Dow\u00a0J, et\u00a0al. The lancet commission on prostate cancer: planning for the surge in cases. Lancet. 2024;403(10437):1683\u2013722.","journal-title":"Lancet"},{"issue":"6","key":"2544_CR3","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.eururo.2018.10.011","volume":"75","author":"T Van den Broeck","year":"2019","unstructured":"Van den Broeck\u00a0T, van den Bergh\u00a0RCN, Arfi\u00a0N, Gross\u00a0T, et\u00a0al. Prognostic value of biochemical recurrence following treatment with curative intent for prostate cancer: a\u00a0systematic review. Eur Urol. 2019;75(6):967\u201387.","journal-title":"Eur Urol"},{"issue":"4","key":"2544_CR4","doi-asserted-by":"publisher","first-page":"517","DOI":"10.2967\/jnumed.118.219352","volume":"60","author":"J Violet","year":"2019","unstructured":"Violet\u00a0J, Jackson\u00a0P, Ferdinandus\u00a0J, et\u00a0al. Dosimetry of (177)Lu-PSMA-617 in metastatic castration-resistant prostate cancer: correlations between Pretherapeutic imaging and whole-body tumor dosimetry with treatment outcomes. J\u00a0Nucl Med. 2019;60(4):517\u201323.","journal-title":"J Nucl Med"},{"key":"2544_CR5","doi-asserted-by":"publisher","first-page":"623","DOI":"10.3389\/fonc.2018.00623","volume":"8","author":"MC Hupe","year":"2018","unstructured":"Hupe\u00a0MC, Philippi\u00a0C, Roth\u00a0D, K, et\u00a0al. Expression of prostate-specific membrane antigen (PSMA) on biopsies is an independent risk Stratifier of prostate cancer patients at time of initial diagnosis. Front Oncol. 2018;8:623.","journal-title":"Front Oncol"},{"issue":"2","key":"2544_CR6","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","volume":"79","author":"N Mottet","year":"2021","unstructured":"Mottet\u00a0N, van den Bergh\u00a0RC, Briers\u00a0E, et\u00a0al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer\u20142020 update. Part\u00a01: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2021;79(2):243\u201362.","journal-title":"Eur Urol"},{"issue":"4","key":"2544_CR7","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s00761-012-2216-z","volume":"18","author":"MP Wirth","year":"2012","unstructured":"Wirth\u00a0MP, Fr\u00f6hner\u00a0M. S3-Leitlinie zur Diagnostik und Therapie des Prostatakarzinoms. Onkologe. 2012;18(4):355\u201364.","journal-title":"Onkologe"},{"issue":"2","key":"2544_CR8","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","volume":"79","author":"P Cornford","year":"2021","unstructured":"Cornford\u00a0P, van den Bergh\u00a0RC, Briers\u00a0E, et\u00a0al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II\u20142020 update: treatment of relapsing and metastatic prostate cancer. Eur Urol. 2021;79(2):263\u201382.","journal-title":"Eur Urol"},{"issue":"12","key":"2544_CR9","first-page":"1288","volume":"20","author":"EM Schaeffer","year":"2022","unstructured":"Schaeffer\u00a0EM, Srinivas\u00a0S, Adra\u00a0N, et\u00a0al. NCCN guidelines\u00ae insights: prostate cancer, version 1.2023: featured updates to the NCCN guidelines. J\u00a0Natl Compr Cancer Netw. 2022;20(12):1288\u201398.","journal-title":"J Natl Compr Cancer Netw"},{"issue":"12","key":"2544_CR10","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor\u00a0O, De Bono\u00a0J, Chi\u00a0KN, et\u00a0al. Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer. N\u00a0Engl J Med. 2021;385(12):1091\u2013103.","journal-title":"N Engl J Med"},{"issue":"3","key":"2544_CR11","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker\u00a0C, Nilsson\u00a0S, Heinrich\u00a0D, et\u00a0al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N\u00a0Engl J Med. 2013;369(3):213\u201323.","journal-title":"N Engl J Med"},{"issue":"4","key":"2544_CR12","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S0090-4295(98)00278-7","volume":"52","author":"SD Sweat","year":"1998","unstructured":"Sweat\u00a0SD, Pacelli\u00a0A, Murphy\u00a0GP, et\u00a0al. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology. 1998;52(4):637\u201340.","journal-title":"Urology"},{"issue":"1","key":"2544_CR13","first-page":"81","volume":"3","author":"DA Silver","year":"1997","unstructured":"Silver\u00a0DA, Pellicer\u00a0I, Fair\u00a0WR, et\u00a0al. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res Off J Am Assoc Cancer Res. 1997;3(1):81\u20135.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"4","key":"2544_CR14","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.eururo.2019.06.030","volume":"76","author":"A Paschalis","year":"2019","unstructured":"Paschalis\u00a0A, Sheehan\u00a0B, Riisnaes\u00a0R, et\u00a0al. Prostate-specific membrane antigen heterogeneity and DNA repair defects in prostate cancer. Eur Urol. 2019;76(4):469\u201378.","journal-title":"Eur Urol"},{"issue":"11","key":"2544_CR15","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1158\/1541-7786.MCR-16-0193","volume":"14","author":"DP Nguyen","year":"2016","unstructured":"Nguyen\u00a0DP, Xiong\u00a0PL, Liu\u00a0H, et\u00a0al. Induction of PSMA and Internalization of an Anti-PSMA mAb in the Vascular Compartment. Mol Cancer Res. 2016;14(11):1045\u201353.","journal-title":"Mol Cancer Res"},{"issue":"2","key":"2544_CR16","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.prnil.2020.07.008","volume":"9","author":"TN Kwan","year":"2021","unstructured":"Kwan\u00a0TN, Spremo\u00a0S, Teh\u00a0AY, et\u00a0al. Performance of Ga-68 PSMA PET\/CT for diagnosis and grading of local prostate cancer. Prostate Int. 2021;9(2):107\u201312.","journal-title":"Prostate Int"},{"issue":"17","key":"2544_CR17","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.3390\/diagnostics14171964","volume":"14","author":"G Rovera","year":"2024","unstructured":"Rovera\u00a0G, Grimaldi\u00a0S, Oderda\u00a0M, et\u00a0al. Comparative performance of 68ga-PSMA-11 PET\/CT and conventional imaging in the primary staging of high-risk prostate cancer patients who are candidates for radical prostatectomy. Diagnostics. 2024;14(17):1964.","journal-title":"Diagnostics"},{"issue":"3","key":"2544_CR18","doi-asserted-by":"publisher","first-page":"425","DOI":"10.2967\/jnumed.116.181768","volume":"58","author":"J Cardinale","year":"2017","unstructured":"Cardinale\u00a0J, Sch\u00e4fer\u00a0M, Bene\u0161ov\u00e1\u00a0M, et\u00a0al. Preclinical evaluation of 18F-PSMA-1007, a\u00a0new prostate-specific membrane antigen ligand for prostate cancer imaging. J\u00a0Nucl Med. 2017;58(3):425\u201331.","journal-title":"J Nucl Med"},{"issue":"7","key":"2544_CR19","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1080\/14737140.2022.2081155","volume":"22","author":"AF Voter","year":"2022","unstructured":"Voter\u00a0AF, Werner\u00a0RA, Pienta\u00a0KJ, et\u00a0al. Piflufolastat F\u201118 (18F-DCFPyL) for PSMA PET imaging in prostate cancer. Expert Rev Anticancer Ther. 2022;22(7):681\u201394.","journal-title":"Expert Rev Anticancer Ther"},{"key":"2544_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40644-020-0290-9","volume":"20","author":"LJ Petersen","year":"2020","unstructured":"Petersen\u00a0LJ, Zacho\u00a0HD. PSMA PET for primary lymph node staging of intermediate and high-risk prostate cancer: an expedited systematic review. Cancer Imaging. 2020;20:1\u20138.","journal-title":"Cancer Imaging"},{"key":"2544_CR21","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s12325-018-0711-3","volume":"35","author":"S Sevcenco","year":"2018","unstructured":"Sevcenco\u00a0S, Klingler\u00a0HC, Eredics\u00a0K, et\u00a0al. Application of Cu-64 NODAGA-PSMA PET in prostate cancer. Adv Ther. 2018;35:779\u201384.","journal-title":"Adv Ther"},{"issue":"8","key":"2544_CR22","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1089\/cbr.2015.1964","volume":"31","author":"B Grubm\u00fcller","year":"2016","unstructured":"Grubm\u00fcller\u00a0B, Baum\u00a0RP, Capasso\u00a0E, et\u00a0al. 64Cu-PSMA-617 PET\/CT imaging of prostate adenocarcinoma: first in-human studies. Cancer Biotherapy Radiopharm. 2016;31(8):277\u201386.","journal-title":"Cancer Biotherapy Radiopharm"},{"key":"2544_CR23","doi-asserted-by":"publisher","first-page":"578093","DOI":"10.3389\/fonc.2021.578093","volume":"11","author":"V Prasad","year":"2021","unstructured":"Prasad\u00a0V, Huang\u00a0K, Prasad\u00a0S, et\u00a0al. In comparison to PSA, interim ga-68-PSMA PET\/CT response evaluation based on modified RECIST\u00a01.1 after 2nd\u00a0cycle is better predictor of overall survival of prostate cancer patients treated with 177Lu-PSMA. Front Oncol. 2021;11:578093.","journal-title":"Front Oncol"},{"issue":"5","key":"2544_CR24","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.eururo.2023.02.002","volume":"83","author":"R Seifert","year":"2023","unstructured":"Seifert\u00a0R, Emmett\u00a0L, Rowe\u00a0SP, et\u00a0al. Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2). Eur Urol. 2023;83(5):405\u201312.","journal-title":"Eur Urol"},{"issue":"8","key":"2544_CR25","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.2967\/jnumed.121.262713","volume":"63","author":"C Schuchardt","year":"2022","unstructured":"Schuchardt\u00a0C, Zhang\u00a0J, Kulkarni\u00a0HR, et\u00a0al. Prostate-specific membrane antigen radioligand therapy using 177Lu-PSMA I&T and 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: comparison of safety, biodistribution, and dosimetry. J\u00a0Nucl Med. 2022;63(8):1199\u2013207.","journal-title":"J Nucl Med"},{"key":"2544_CR26","volume-title":"Presented at the EAU annual congress paris 2024","author":"Guidelines E. Edn.","year":"2024","unstructured":"Guidelines E. Edn.. Presented at the EAU annual congress paris 2024. 2024."},{"issue":"6","key":"2544_CR27","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.annonc.2023.02.015","volume":"34","author":"K Fizazi","year":"2023","unstructured":"Fizazi\u00a0K, Gillessen\u00a0S. Updated treatment recommendations for prostate cancer from the ESMO clinical practice guideline considering treatment intensification and use of novel systemic agents. Ann Oncol. 2023;34(6):557\u201363.","journal-title":"Ann Oncol"},{"issue":"10","key":"2544_CR28","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","volume":"21","author":"EM Schaeffer","year":"2023","unstructured":"Schaeffer\u00a0EM, Srinivas\u00a0S, Adra\u00a0N, et\u00a0al. Prostate cancer, version 4.2023, NCCN clinical practice guidelines in oncology. J\u00a0Natl Compr Canc Netw. 2023;21(10):1067\u201396.","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"2544_CR29","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1097\/JU.0000000000003452","volume":"209","author":"W Lowrance","year":"2023","unstructured":"Lowrance\u00a0W, Dreicer\u00a0R, Jarrard\u00a0DF, et\u00a0al. Updates to advanced prostate cancer: aUA\/SUO guideline (2023). J\u00a0Urol. 2023;209(6):1082\u201390.","journal-title":"J Urol"},{"issue":"10276","key":"2544_CR30","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","volume":"397","author":"MS Hofman","year":"2021","unstructured":"Hofman\u00a0MS, Emmett\u00a0L, Sandhu\u00a0S, et\u00a0al. (177Lu) Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a\u00a0randomised, open-label, phase\u00a02\u00a0trial. Lancet. 2021;397(10276):797\u2013804.","journal-title":"Lancet"},{"issue":"10459","key":"2544_CR31","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","volume":"404","author":"MJ Morris","year":"2024","unstructured":"Morris\u00a0MJ, Castellano\u00a0D, Herrmann\u00a0K, et\u00a0al. 177Lu-PSMA-617 versus a\u00a0change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMafore): a\u00a0phase\u00a03, randomised, controlled trial. Lancet. 2024;404(10459):1227\u201339.","journal-title":"Lancet"},{"issue":"10","key":"2544_CR32","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/S1470-2045(24)00440-6","volume":"25","author":"AA Azad","year":"2024","unstructured":"Azad\u00a0AA, Bressel\u00a0M, Tan\u00a0H, et\u00a0al. Sequential ((177)Lu)Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (upfrontPSMA): a\u00a0multicentre, open-label, randomised, phase\u00a02\u00a0study. Lancet Oncol. 2024;25(10):1267\u201376.","journal-title":"Lancet Oncol"},{"issue":"3","key":"2544_CR33","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.eururo.2023.08.026","volume":"85","author":"RS Eapen","year":"2024","unstructured":"Eapen\u00a0RS, Buteau\u00a0JP, Jackson\u00a0P, et\u00a0al. Administering ((177)Lu)Lu-PSMA-617 prior to radical prostatectomy in men with high-risk Localised prostate cancer (LuTectomy): a\u00a0single-centre, single-arm, phase\u00a01\/2 study. Eur Urol. 2024;85(3):217\u201326.","journal-title":"Eur Urol"},{"issue":"9","key":"2544_CR34","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.1007\/s00259-022-05744-6","volume":"49","author":"PE Hartrampf","year":"2022","unstructured":"Hartrampf\u00a0PE, Weinzierl\u00a0FX, Buck\u00a0AK, et\u00a0al. Matched-pair analysis of ((177)Lu)Lu-PSMA I&T and ((177)Lu)Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2022;49(9):3269\u201376.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"2544_CR35","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S1470-2045(24)00135-9","volume":"25","author":"L Emmett","year":"2024","unstructured":"Emmett\u00a0L, Subramaniam\u00a0S, Crumbaker\u00a0M, et\u00a0al. (177Lu) Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase\u00a02\u00a0trial. Lancet Oncol. 2024;25(5):563\u201371.","journal-title":"Lancet Oncol"},{"issue":"9","key":"2544_CR36","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1007\/s00259-023-06255-8","volume":"50","author":"C Kratochwil","year":"2023","unstructured":"Kratochwil\u00a0C, Fendler\u00a0WP, Eiber, et\u00a0al. Joint EANM\/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging. 2023;50(9):2830\u201345.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"2544_CR37","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1007\/s00259-023-06585-7","volume":"51","author":"J Kim","year":"2024","unstructured":"Kim\u00a0J, Lee\u00a0S, Kim\u00a0D, et\u00a0al. Combination of ((18)F)FDG and ((18)F)PSMA-1007 PET\/CT predicts tumour aggressiveness at staging and biochemical failure postoperatively in patients with prostate cancer. Eur J Nucl Med Mol Imaging. 2024;51(6):1763\u201372.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"2544_CR38","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1097\/RLU.0000000000005587","volume":"50","author":"L Bian","year":"2025","unstructured":"Bian\u00a0L, Li\u00a0P, Wang\u00a0X, et\u00a0al. Dual-tracer 18 F\u2011FDG and 68\u202fga-PSMA PET\/CT imaging of heterogeneous phenotypes of metastatic castration-resistant prostate cancer for predicting response to novel hormone therapy. Clin Nucl Med. 2025;50(2):143\u20139.","journal-title":"Clin Nucl Med"},{"key":"2544_CR39","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s12149-018-1264-x","volume":"32","author":"C Mair","year":"2018","unstructured":"Mair\u00a0C, Warwitz\u00a0B, Fink\u00a0K, et\u00a0al. Radiation exposure after 177 Lu-DOTATATE and 177 Lu-PSMA-617 therapy. Ann Nucl Med. 2018;32:499\u2013502.","journal-title":"Ann Nucl Med"},{"key":"2544_CR40","doi-asserted-by":"crossref","unstructured":"Handayani W, Chantadisai M, Phromphao B, et\u00a0al. Comparative post-therapeutic dosimetry between 2D planar-based and hybrid-based methods for personalized Lu-177 treatment. Ann Nucl Med. 2024; 1\u201310.","DOI":"10.1007\/s12149-024-01960-2"},{"issue":"11","key":"2544_CR41","doi-asserted-by":"publisher","first-page":"12477","DOI":"10.18632\/oncotarget.7245","volume":"7","author":"H Ahmadzadehfar","year":"2016","unstructured":"Ahmadzadehfar\u00a0H, Eppard\u00a0E, K\u00fcrpig\u00a0S, et\u00a0al. Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer. Oncotarget. 2016;7(11):12477.","journal-title":"Oncotarget"},{"issue":"3","key":"2544_CR42","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.euo.2023.07.018","volume":"7","author":"M Kafka","year":"2024","unstructured":"Kafka\u00a0M, Horninger\u00a0A, di Santo\u00a0G, et\u00a0al. Real-world outcomes and predictive biomarkers for 177lutetium prostate-specific membrane antigen ligand treatment in metastatic castration-resistant prostate cancer: a\u00a0European association of urology young academic urologists prostate cancer working group multi-institutional observational study. Eur Urol Oncol. 2024;7(3):421\u20139.","journal-title":"Eur Urol Oncol"},{"issue":"13","key":"2544_CR43","doi-asserted-by":"publisher","first-page":"4727","DOI":"10.1007\/s00259-022-05910-w","volume":"49","author":"PE Hartrampf","year":"2022","unstructured":"Hartrampf\u00a0PE, Bundschuh\u00a0RA, Weinzierl\u00a0FX, et\u00a0al. mCRPC patients with PSA fluctuations under radioligand therapy have comparable survival benefits relative to patients with sustained PSA decrease. Eur J Nucl Med Mol Imaging. 2022;49(13):4727\u201335.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"2544_CR44","doi-asserted-by":"publisher","first-page":"e222148","DOI":"10.1148\/radiol.222148","volume":"308","author":"A Gafita","year":"2023","unstructured":"Gafita\u00a0A, Djaileb\u00a0L, Rauscher\u00a0I, et\u00a0al. Response evaluation criteria in PSMA PET\/CT (RECIP 1.0) in metastatic castration-resistant prostate cancer. Radiology. 2023;308(1):e222148.","journal-title":"Radiology"},{"key":"2544_CR45","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1007\/s00259-018-4222-x","volume":"46","author":"A Yordanova","year":"2019","unstructured":"Yordanova\u00a0A, Linden\u00a0P, Hauser\u00a0S, et\u00a0al. Outcome and safety of rechallenge (177 Lu) Lu-PSMA-617 in patients with metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2019;46:1073\u201380.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2544_CR46","doi-asserted-by":"crossref","unstructured":"Santo G, Di Santo G, Sviridenko A, et\u00a0al. Efficacy and safety of rechallenge with (177Lu) Lu-PSMA-I&T radioligand therapy in metastatic castration resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2024; 1\u201312.","DOI":"10.1007\/s00259-024-06905-5"},{"key":"2544_CR47","doi-asserted-by":"crossref","unstructured":"Rosar F, Schuler J, Burgard C, et\u00a0al. Efficacy and safety of rechallenge (177Lu) Lu-PSMA-617 RLT after initial partial remission in patients with mCRPC: evaluation of a\u00a0prospective registry (REALITY study). Eur J Nucl Med Mol Imaging. 2024; 1\u201312.","DOI":"10.1007\/s00259-024-06825-4"},{"issue":"1","key":"2544_CR48","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.radcr.2024.10.084","volume":"20","author":"Y-Y Huang","year":"2025","unstructured":"Huang\u00a0Y\u2011Y, Lin\u00a0T\u2011C, Yang\u00a0S\u2011H, et\u00a0al. Radiation safety and dialysate analysis in hemodialysis following Lu-177-PSMA-617 therapy: a\u00a0case report. Radiol Case Rep. 2025;20(1):805\u20139.","journal-title":"Radiol Case Rep"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-025-02544-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00508-025-02544-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-025-02544-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T06:01:53Z","timestamp":1749189713000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00508-025-02544-4"}},"subtitle":["Joint statement of the Austrian Society of Nuclear Medicine and Theranostics and the Austrian Society of Urology and Andrology"],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":48,"journal-issue":{"issue":"S4","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["2544"],"URL":"https:\/\/doi.org\/10.1007\/s00508-025-02544-4","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"17 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"S. Mirzaei, G. Schweighofer-Zwink, H. Ofner, J. Bektic, H. Fajkovic, E. von Guggenberg, A. Ponholzer, G. Kramer, L. Lusuardi, M. Gabriel, T. Traub-Weidinger, M. Hacker and S.F. Shariat declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"For this article no studies with human participants or animals were performed by any of the authors. All studies mentioned were in accordance with the ethical standards indicated in each case.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}